Wall Street brokerages predict that bluebird bio Inc (NASDAQ:BLUE) will post earnings of ($2.83) per share for the current fiscal quarter, according to Zacks. Eight analysts have provided estimates for bluebird bio’s earnings, with estimates ranging from ($3.20) to ($2.55). bluebird bio reported earnings of ($2.52) per share in the same quarter last year, which indicates a negative year-over-year growth rate of 12.3%. The firm is expected to issue its next earnings results on Wednesday, February 20th.
According to Zacks, analysts expect that bluebird bio will report full year earnings of ($10.76) per share for the current fiscal year, with EPS estimates ranging from ($11.17) to ($10.25). For the next fiscal year, analysts expect that the firm will post earnings of ($11.52) per share, with EPS estimates ranging from ($12.95) to ($9.13). Zacks’ EPS averages are a mean average based on a survey of research firms that cover bluebird bio.
bluebird bio (NASDAQ:BLUE) last announced its quarterly earnings results on Thursday, November 1st. The biotechnology company reported ($2.73) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($2.90) by $0.17. The firm had revenue of $11.50 million during the quarter, compared to the consensus estimate of $6.90 million. bluebird bio had a negative return on equity of 31.50% and a negative net margin of 1,326.02%. The firm’s quarterly revenue was up 49.2% compared to the same quarter last year. During the same period in the prior year, the company posted ($1.73) earnings per share.
BLUE has been the subject of a number of research analyst reports. Cantor Fitzgerald set a $122.00 price target on bluebird bio and gave the company a “sell” rating in a report on Wednesday, September 5th. ValuEngine raised bluebird bio from a “buy” rating to a “strong-buy” rating in a report on Tuesday, October 2nd. Piper Jaffray Companies downgraded bluebird bio from an “overweight” rating to a “neutral” rating and lowered their price target for the company from $240.00 to $120.00 in a report on Thursday. Oppenheimer reaffirmed a “hold” rating on shares of bluebird bio in a report on Tuesday, November 27th. Finally, William Blair reaffirmed a “buy” rating on shares of bluebird bio in a report on Tuesday. Two investment analysts have rated the stock with a sell rating, nine have given a hold rating and seventeen have assigned a buy rating to the company’s stock. The company has an average rating of “Buy” and an average price target of $194.80.
In other bluebird bio news, Director James Mandell sold 1,000 shares of the business’s stock in a transaction that occurred on Monday, September 10th. The stock was sold at an average price of $150.77, for a total value of $150,770.00. Following the completion of the sale, the director now owns 1,568 shares in the company, valued at $236,407.36. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, insider David Davidson sold 5,000 shares of the business’s stock in a transaction that occurred on Tuesday, October 2nd. The shares were sold at an average price of $139.32, for a total value of $696,600.00. Following the completion of the sale, the insider now owns 29,905 shares of the company’s stock, valued at approximately $4,166,364.60. The disclosure for this sale can be found here. In the last quarter, insiders sold 21,490 shares of company stock valued at $2,901,186. 3.00% of the stock is owned by company insiders.
Several institutional investors have recently added to or reduced their stakes in BLUE. Stratos Wealth Partners LTD. purchased a new stake in shares of bluebird bio during the third quarter worth approximately $106,000. Belpointe Asset Management LLC purchased a new stake in shares of bluebird bio during the third quarter worth approximately $110,000. NuWave Investment Management LLC raised its stake in shares of bluebird bio by 10,811.1% during the third quarter. NuWave Investment Management LLC now owns 982 shares of the biotechnology company’s stock worth $143,000 after purchasing an additional 973 shares during the last quarter. Harel Insurance Investments & Financial Services Ltd. raised its stake in shares of bluebird bio by 635.0% during the third quarter. Harel Insurance Investments & Financial Services Ltd. now owns 1,154 shares of the biotechnology company’s stock worth $167,000 after purchasing an additional 997 shares during the last quarter. Finally, Tower Research Capital LLC TRC purchased a new stake in shares of bluebird bio during the second quarter worth approximately $201,000.
BLUE traded down $6.62 on Friday, reaching $102.23. The company’s stock had a trading volume of 1,024,569 shares, compared to its average volume of 690,709. The company has a market capitalization of $5.95 billion, a price-to-earnings ratio of -13.26 and a beta of 2.37. bluebird bio has a fifty-two week low of $100.99 and a fifty-two week high of $236.17.
bluebird bio Company Profile
bluebird bio, Inc, a clinical-stage biotechnology company, focuses on developing transformative gene therapies for severe genetic diseases and cancer. Its product candidates include Lenti-D that is in Phase II/III clinical trials for the treatment of cerebral adrenoleukodystrophy, a rare hereditary neurological disorder; and LentiGlobin, which is in various clinical studies for the treatment of transfusion- transfusion-dependent ß-thalassemia and severe sickle cell disease.
Featured Article: Fundamental Analysis – How It Helps Investors
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for bluebird bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio and related companies with MarketBeat.com's FREE daily email newsletter.